Fig. 8: HDAC9 inhibition enhanced the effect of cisplatin on GC tumor suppression.
From: Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer
a Knockdown of HDAC9 in SGC-7901 cells resulted in reduced subcutaneous tumorigenic ability and enhanced the antitumor effect of cisplatin in nude mice. b The tumor volumes were monitored three times weekly. The combination of siHDAC9 and cisplatin showed greater antitumor effect than each single-agent treatment. c The dissected xenograft tumors were weighed at the end of treatment. d HDAC9 expression and cell proliferation and apoptosis were assessed by HDAC9 and Ki-67 immunohistochemical staining and a TUNEL assay using serial sections. The HDAC9-negative area denoted by the dotted line indicates the location of siHDAC9 injection. Scale bars = 100 μm. The error bars indicate the means ± SDs; *p < 0.05, **p < 0.01, ***p < 0.001 versus the control group
